Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ligand Pharmaceuticals Inc.

www.ligand.com

Latest From Ligand Pharmaceuticals Inc.

Ono Bulks Up MAb R&D With Second Swiss Biotech Deal

Human-derived monoclonal antibodies targeted against neurodegenerative diseases is the subject of a deal between Japan's Ono Pharmaceutical and Zurich-based biotech Neurimmune.

Deals Neurology

Deal Watch: AbbVie Bets On Turnstone’s Cancer Immunotherapy Technology

AbbVie takes options on three oncolytic virus immunotherapies under development at Turnstone. Amgen and CytomX swap IP in cancer immunotherapy collaboration, while Nicox and pSivida will team to fight glaucoma and other eye diseases.

Deals Business Strategies

Pipeline Watch: Phase III Readouts For Gilenya, Duvelisib, Trimbow

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Deal Watch: WuXi/Gloria License PD-1 Inhibitor To Arcus For Up To $816m

WuXi Biologics and Harbin Gloria will get $18.5m up front for the Phase I asset GLS-010. Also, Cerecor divests depression drug to Janssen for up to $45m and Perrigo sells its API division for $110m in cash.

Deals Business Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register